Skip to main content
. 2019 Feb 13;3(4):508–518. doi: 10.1182/bloodadvances.2018027409

Figure 2.

Figure 2.

Outcomes of patients treated with pracinostat plus azacitidine. (A) OS for the whole cohort. (B) PFS for the whole population. (C) OS stratified by response. The plot shows how the effect of analyzing CR (as a baseline covariate) produces artificial difference; the difference between the overall curve and the curve obtained by censoring at time of CR gives a more realistic view. (D) OS stratified by cytogenetic risk group.